MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1

Hear from international lung cancer experts Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, as they answer audience questions from a live CCO Webinar on METex14 mutation–positive NSCLC, from incorporation of testing for MET exon 14 alterations into standard of care to optimal use of MET-targeted therapies in this setting.